Efficacy of concurrent cetuximab vs. 5-fluorouracil/carboplatin or high-dose cisplatin with intensity-modulated radiation therapy (IMRT) for locally-advanced head and neck cancer (LAHNSCC) Academic Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Carcinoma, Squamous Cell
  • Head and Neck Neoplasms
  • Radiotherapy, Intensity-Modulated

abstract

  • Although 5FU/carboplatin patients were sicker and experienced greater toxicity than cisplatin patients, no significant difference was found in all endpoints. In contrast, despite similar pretreatment characteristics, outcomes for cetuximab vs. 5FU/carboplatin were significantly worse. We feel that caution should be used with routine use of cetuximab in the management of LAHNSCC.

publication date

  • January 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5125726

Digital Object Identifier (DOI)

  • 10.1016/j.oraloncology.2014.07.001

PubMed ID

  • 25132089

Additional Document Info

start page

  • 947

end page

  • 55

volume

  • 50

number

  • 10